Herceptin works by attaching itself to the HER2 receptors on the surface of breast cancer cells and blocking them from receiving growth signals. By blocking the signals, Herceptin can slow or stop the growth of the breast cancer. Herceptin is an example of an immune targeted therapy.

How Herceptin works the mechanism of action?

Herceptin works by attaching itself to the HER2 receptors on the surface of breast cancer cells and blocking them from receiving growth signals. By blocking the signals, Herceptin can slow or stop the growth of the breast cancer. Herceptin is an example of an immune targeted therapy.

How does trastuzumab inhibit HER2 activity?

Trastuzumab reduces signaling mediated by HER2 through the phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) cascades. Reduced downstream signaling through these pathways induces the cyclin-dependent kinase inhibitor p27kip1, which promotes cell-cycle arrest and apoptosis [9, 10].

What is HER2 function?

HER2 is a membrane tyrosine kinase and oncogene that is overexpressed and gene amplified in about 20% of breast cancers. When activated it provides the cell with potent proliferative and anti-apoptosis signals and it is the major driver of tumor development and progression for this subset of breast cancer.

How does Herceptin and Perjeta work?

Perjeta targets a different area on the HER2 receptor than Herceptin does, so it’s believed to work in a way that is complementary to Herceptin. By blocking the signals, Perjeta can slow or stop the growth of the breast cancer. Perjeta and Herceptin are examples of immune targeted therapy.

What does Herceptin inhibit?

The most well known effect of trastuzumab is the inhibition of the MAPK and PI3K/Akt pathways (Figure ​1), which leads to an increase in cell cycle arrest, and the suppression of cell growth and proliferation.

Is Herceptin a targeted therapy?

Herceptin (chemical name: trastuzumab) is a HER2 inhibitor targeted therapy. Herceptin works against HER2-positive breast cancers by blocking the ability of the cancer cells to receive chemical signals that tell the cells to grow.

Is Herceptin an EGFR inhibitor?

Inactivation of epidermal growth factor receptor (EGFR) family members represents a promising strategy for the development of selective therapies against epithelial cancers. Current anti-EGFR therapies, such as cetuximab (Erbitux), gefitinib (Iressa), or trastuzumab (Herceptin), target EGFR or HER-2 but not both.

Why is PERJETA given before Herceptin?

Updated results from the APHINITY trial confirmed that adding Perjeta (chemical name: pertuzumab) to Herceptin (chemical name: trastuzumab) and chemotherapy after surgery for early-stage HER2-positive breast cancer reduces the risk of recurrence (the cancer coming back) and slightly improves survival.

What is the difference between PERJETA and Herceptin?

PERJETA is given with another targeted treatment called Herceptin. Both treatments are designed to fight cancer cells that have too many HER2 receptors, but in different ways. Since normal cells also have HER2 receptors (just not as many), PERJETA and Herceptin can also affect healthy cells.

Does Herceptin lower immunity?

Does trastuzumab (Herceptin) lower your immune system? Having trastuzumab (Herceptin) could mean you’re more at risk of getting coronavirus or becoming very ill if you get it. The risk is likely to be higher if you’re having it with chemotherapy. However, being fully vaccinated against Covid-19 reduces the risk.

What is the mechanism of action of Herceptin?

Herceptin: mechanisms of action and resistance HER-2 is overexpressed in 20-25% of invasive breast cancers and is associated with an aggressive tumor phenotype and reduced survival rate. The HER-2 status of a tumor is the critical determinant of response to the HER-2-targeted antibody Herceptin.

How does trastuzumab (Herceptin) work?

Trastuzumab (Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Herceptin is approved for the treatment of early-stage breast cancer that is H uman E pidermal growth factor R eceptor 2

Does Herceptin cause Grade 3 neutropenia?

In randomized, controlled clinical trials, the per-patient incidences of NCI-CTC Grade 3-4 neutropenia and of febrile neutropenia were higher in patients receiving Herceptin in combination with myelosuppressive chemotherapy as compared to those who received chemotherapy alone.

Does Herceptin cause cardiomyopathy?

Herceptin administration can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving Herceptin with anthracycline-containing chemotherapy regimens. In a pivotal adjuvant trial, one patient who developed CHF died of cardiomyopathy